BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
17 Mayo 2024 - 10:15AM
UK Regulatory
BioNTech SE Shareholders Approve All Agenda Items at the Annual
General Meeting 2024
MAINZ, Germany, May 17, 2024 (GLOBE
NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the
“Company”) held its Annual General Meeting (“AGM”) today, May 17,
2024. A total of 87.51 per cent of the share capital was
represented at the virtual assembly. There were 14 items on the
agenda of the AGM. All resolutions proposed on the agenda items put
to the vote at today’s AGM were approved by a large majority of the
shareholders.
“The past few years marked a leap in competence
for BioNTech,” said Helmut Jeggle, Chairman of the
Supervisory Board of BioNTech. “With the development and
commercialization of a leading COVID-19 vaccine, BioNTech has shown
that it can deliver against targeted objectives successfully.
Today, BioNTech’s robust financial position is an excellent
foundation for its transformation into a multi-product company,
with particular focus on achieving commercial readiness in
oncology.”
“2023 was a year in which we made important
progress in many areas: We maintained a leading position in the
COVID-19 vaccine market, published encouraging data for candidates
in our oncology pipeline and launched potentially registrational
trials. Additionally, we have strengthened our organization in
preparation for the next phase of growth, particularly with regards
to our planned product launches in oncology,” said Prof.
Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We
believe that our therapies under development, once approved, have
the potential to complement or replace established cancer treatment
approaches in many areas in the future.”
The voting results for all agenda items can be
seen on the Annual General Meeting 2024 website under the section
‘Voting Results’. The speech by Prof. Ugur Sahin, M.D., and the
slides presented at the AGM 2024 can be found in section ‘Speeches
and Presentations’ under the same link.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next
generation immunotherapy company pioneering novel therapies for
cancer and other serious diseases. BioNTech exploits a wide array
of computational discovery and therapeutic drug platforms for the
rapid development of novel biopharmaceuticals. Its broad portfolio
of oncology product candidates includes individualized and
off-the-shelf mRNA-based therapies, innovative chimeric antigen
receptor (CAR) T cells, several protein-based therapeutics,
including bispecific immune checkpoint modulators, targeted cancer
antibodies and antibody-drug conjugate (ADC) therapeutics, as well
as small molecules. Based on its deep expertise in mRNA vaccine
development and in-house manufacturing capabilities, BioNTech and
its collaborators are developing multiple mRNA vaccine candidates
for a range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global and specialized pharmaceutical collaborators,
including Biotheus, DualityBio, Fosun Pharma, Genentech, a member
of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and
Regeneron.
For more information, please visit
www.BioNTech.com.
Forward-Looking Statements
This press release contains “forward-looking statements” of
BioNTech within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements may include,
but may not be limited to, statements concerning BioNTech’s
financial position; BioNTech’s research and development programs,
including statements characterizing timing, related preparatory
work, and the availability of results; and BioNTech’s preparations
for potential product launches in oncology. Any forward-looking
statements in this press release are based on BioNTech’s current
expectations and beliefs of future events. The forward-looking
statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties, and other factors, many of which are beyond
BioNTech’s control, and which could cause actual results to differ
materially from those expressed or implied by these forward-looking
statements.
You should review the risks and uncertainties
described under the heading “Risk Factors” in BioNTech’s Report on
Form 6-K for the period ended March 31, 2024 and in subsequent
filings made by BioNTech with the SEC, which are available on the
SEC’s website at www.sec.gov. These forward-looking statements
speak only as of the date hereof. Except as required by law,
BioNTech disclaims any intention or responsibility for updating or
revising any forward-looking statements contained in this press
release in the event of new information, future developments or
otherwise.
CONTACTS
Investor Relations
Victoria Meissner, M.D.
+1 617 528 8293
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
Biontech (LSE:0A3M)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Biontech (LSE:0A3M)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024